Table 2.
Comparisons of substances and metabolites concentrations between patients and their relatives.
| n * | n° | Patients | Relatives | p | |
|---|---|---|---|---|---|
| Urine | |||||
| Dorzolamide [ng/mL, median (IQR)] | 50 | 0 | 245 (116; 501) # | 0 (0; 0) | <0.001 |
| N-Deethyl-dorzolamide [ng/mL, median (IQR)] | 50 | 0 | 81.1 (35.9; 125.3) # | 0 (0; 0) | <0.001 |
| N-Acetyl-dorzolamide [ng/mL, median (IQR)] | 22 | 21 | 0.77 (0.64; 0.84) # | 0 (0; 0) | <0.001 |
| Brinzolamide [ng/mL, median (IQR)] | 29 | 0 | 38.9 (20.4; 79.2) | 0 (0; 0) | <0.001 |
| O-Desmethyl-brinzolamide [ng/mg, median (IQR)] | 1 | 28 | - | 0 (0; 0) | |
| Acetazolamide [ng/mL, median (IQR)] | 10 | 0 | 72.8 (20.7; 437.3) | 0 (0; 0) | |
| Hair | |||||
| Dorzolamide [ng/mg, median (IQR)] | 40 | 9 | 0.48 (0.1; 0.98) # | 0 (0; 0) | <0.001 |
| N-Deethyl-dorzolamide [ng/mg, median (IQR)] | 26 | 23 | 0.07 (0.06; 0.08) # | 0 (0; 0) | <0.001 |
| N-Acetyl-dorzolamide [ng/mg, median (IQR)] | 0 | 0 | - | - | |
| Brinzolamide [ng/mg, median (IQR)] | 14 | 14 | 0.4 (0.13; 1.95) | 0 (0; 0) | <0.001 |
| O-Desmethyl-brinzolamide [ng/mg, median (IQR)] | 0 | 0 | 0 (0; 0) | 0 (0; 0) | |
| Acetazolamide [ng/mg, median (IQR)] | 1 | 9 | - | 0 (0; 0) | 0.05 |
n *, number of patients in which the concentration was > LOQ; n°, number of patients in which the concentration was >0 and <LOQ; p refers to the Wilcoxon sum-rank test; IQR, Interquartile range; LOQ, limit of quantification. # comparison of concentrations of dorzolamide and its related metabolites: paired samples Wilcoxon sum-rank test p < 0.001.